GSK and Dundee to find new drugs for tropical diseases with Wellcome Trust funding
This article was originally published in Scrip
The development of new drugs for neglected tropical diseases is the subject of the latest agreement between GlaxoSmithKline and the University of Dundee. The partnership will focus on a series of preclinical compounds for leishmaniasis, Chagas' disease and African sleeping sickness, supported by a grant of £8.6 million from the Wellcome Trust.
You may also be interested in...
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.